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. When linked with an increase in the duration of clinical phase testing over the past 10 years, to an average of 6.8 years based on a recent estimate (Lamberti and Getz, 2015) , the cost of bringing a new drug to market has increased to well over $2 billion (Pammoli et al., 2011) . Increased risk and clinical development cycle time are in part due to a larger proportion of CNS drug candidates. to model blood brain barrier (BBB) transport and within brain distribution (Summerfield and Dong, 2013) . In addition to multiple tools to evaluate the pharmacokinetic aspects of CNS distribution of candidate molecules, application of modeling and simulation science to integrate CNS physiology with pharmacokinetics and pharmacodynamics, so-called physiology-based pharmacokinetic, pharmacodynamic (PBPKPD) models, has shown much promise in being able to translate mixed platform data sources (for example, animal and human target receptor/transporter binding and functional effects in vitro, and species-specific physiology) to predict pharmacodynamics in humans (Taneja et al., 2016; van den Brink et al., 2018) . Recent noteworthy examples are application of PBPKPD models to predict dopamine D2 receptor occupancy of antipsychotic drugs (Johnson et al., 2016) , and to support dose selection in proof of concept studies of drug candidates for the treatment of chronic pain (Yassen et al., 2013) . To varying extents, all of these approaches address an integrated drug discovery strategy, a so-called three pillars approach, suggesting that demonstration of 1) compound exposure in the target biophase, 2) compound binding to its intended target(s), and 3) pharmacologic effect, is necessary to discharge risk in clinical drug development (Morgan et al., 2012) .
Microdialysis represents an in vivo technique that has been used for several years to measure pharmacodynamic effects in the brain through altered neurotransmitter levels in extracellular fluid (ECF) pre-versus post-compound administration (Watson et al. ,
). This technique allows rich temporal sampling within subjects, thus resulting in a significant reduction in the number of animals needed. More recently, it has been used to measure compound exposure in the ECF, which is the biophase for many drug targets (since it is in direct contact with brain parenchymal membrane-bound target receptors and transporters). Advances in analytical detection technology, and in microdialysis probe design that enhances and simplifies drug recovery for quantitation purposes (Cremers et al., 2009; Sood et al., 2009) have supported this second application. By enabling measurement of biophase drug exposure and functional pharmacologic response (e.g. neurotransmitter concentrations), microdialysis addresses the first and third 'pillars' of the aforementioned integrated drug discovery strategy, and has been used extensively to support PBPKPD modeling (van den Brink et al., 2017; Yamamoto et al., 2017a; Yamamoto et al., 2017b; Yamamoto et al., 2017c) . Largely, however, the technique has been confined to rodents. While microdialysis in rodents connects biophase compound exposure with pharmacodynamic effect, confidence that this connectivity in rats will translate to humans can be tenuous, particularly for novel targets, in which mechanistic validation between target engagement and demonstrated efficacy would likely not exist. Accordingly, capability to apply the strengths of microdialysis to species that are evolutionarily closer to humans, such as non-human primates (NHP), would be advantageous, both from the standpoint of connecting target tissue exposure to pharmacodynamic effect, and to identifying drug effect-related biomarkers that could be translated to humans. As well, from a pharmacokinetic standpoint, expression of several uptake and efflux transporters at the
BBB was recently shown to be consistently similar between NHP's and humans, which was not the case for rats (Hoshi et al., 2013) . following a 0.1 mg/kg intravenous bolus dose of the drug. These measurements supported development of a population-based PK model. Both pre-and post-dose concentrations of dopamine in the two brain regions were also measured by microdialysis. Application of the PK model afforded simulation of D-amphetamine concentrations in the ECF following higher doses of the drug. Doses used were from a published NHP study (Jedema et al., 2014) that measured dopamine concentrations in both brain regions. These PK model-based simulations enabled visualization of Damphetamine concentration and dopamine response relationships in brain ECF. For reference purposes, studies in rats that measured D-amphetamine concentrations in plasma, ECF and CSF were conducted following the same 0.1 mg/kg intravenous bolus dose of the drug. As with NHPs, PK model simulations supported visualization of dopamine response in relation to ECF drug exposure. Finally, food was sometimes offered concealed so as to provide additional environmental enrichment. Following surgery, animals were single housed until completion of an experiment. In the interim period between surgery and sampling from the three matrices (plasma, brain ECF and CSF), animals were trained to sit stress-free in primate chairs so that samples could be obtained while animals were awake.
Coordinates for microdialysis probe placement were determined by using a magnetic resonance imaging (MRI) scan, applying 3D viewer software (Syngo MR B17, Siemens AG, Munich, Germany) with subsequent matching to a primate brain map (Martin and Bowden, 2000) . Images were obtained with a 7 cm loop-coil in a 3 Tesla Siemens -75, -45, -15, 15, 45, 75, 105, 135, 165, 195, 225, 255, 285, 315 minutes. Dextroamphetamine was administered as a bolus dose at 0.1 mg/kg (1 mL/kg in sterile 0.9% sodium chloride) into the brachial vein via a catheter, which was subsequently flushed with approximately 1.0 mL of sterile saline. In all studies, doses were prepared fresh daily. In the case of ECF collections for dopamine analysis, D-amphetamine was administered on two separate occasions; there was a two week washout period between these two sessions.
CSF sampling was by a catheter that was surgically placed in the cisterna magna through the atlantooccipital membrane, with the other end of the catheter connected to a titanium port placed between the animal's shoulder blades. Sedation and anesthesia for surgical implantation of the catheter were accomplished as described for microdialysis guide cannula implantation. The skin of the animal was incised from the posterior midline at the external occipital protuberance of the skull towards the atlas.
Muscle and fat tissue were pushed outward using blunt forceps until the atlantooccipital membrane was exposed. A small needle was pushed through the membrane and the opening enlarged using blunt forceps, until the catheter (polyurethane CNC-5POGE;
Norfolk-Acces, IL, USA) could be placed. The catheter was fixed in place by gluing of collars on either side of the membrane. Finally, the port (Titan port CP6AC-5NC;
Norfolk-Acces, IL, USA) was connected and put into place between the shoulder blades of the animal. Animal was allowed to recover for at least two weeks prior to being used in an experiment. Samples (0.5 mL) were collected into polypropylene vials and stored at -80  C until time of analysis. The following time points were collected: 0 (pre-dose), and 60, 120, 180 and 240 minutes post-administration of D-amphetamine.
Sampling of whole blood (1 mL) was from a femoral or tail vein. Samples were collected into K2-EDTA tubes and placed on ice. Within 45 minutes of collection, samples were centrifuged at 4000 rpm for 10 minutes at 4  C. Resultant plasma samples were transferred to polypropylene tubes and stored at -80  C until time of analysis. The following time points were collected: 0 (pre-dose), and 60, 120, 180, 240, 300 and 360 minutes post-administration of D-amphetamine.
Collections for the three matrices were taken while animals were sitting fully awake in a chair. Prior to actual sampling for analysis of D-amphetamine and dopamine, mock sample drug administration and sample collection sessions were conducted for increasing lengths of time in order to train animals. Positive reinforcement was used during these training sessions; this consisted of fruit juice (Ribena, 4.6% sugar by w/v) offerings towards the middle and end of a training session. Fruit juice was not offered during an actual experiment. At the conclusion of all studies, animals were euthanized using an intravenous overdose of pentobarbital. Microdialysis probe location was verified at this time.
Rats
Male Wistar rats (average weight 462 grams purchased from Harlan, Horst, The Netherlands) were used for collection of brain ECF, CSF and whole blood. A total of 11 animals were used in these experiments. After arrival, animals were housed in groups of five in polypropylene cages (40 x 50 x 20 cm) with a wire mesh top in a temperature controlled (22  2  C) and humidity controlled (55%  15%) environment on a 12-hour light cycle (07.00 -19.00). After surgery, animals were housed individually (cages 30 x 30 x 30 cm), although they remained in proximity to their original cage mates to allow auditory, olfactory and visual contact. No behavioral changes were observed following surgery. Standard diet (Diets RMH-B 2818; ABDiets, Woerden, The Netherlands) and domestic quality water were available ad libitum. Rats received tissues, sizzle nest and tunnels for enrichment benefits. For PK studies, blood samples were collected from all animals (6 total), for a total of 30 samples measured to support PK model development.
ECF samples for analysis of D-amphetamine were collected from four animals
(MetaQuant microdialysis probes inserted into the medial PFC), for a total of 44 samples measured to support model development. CSF samples for analysis of Damphetamine were collected from five animals (four of which were the same as those used for ECF collection from the medial PFC) via cannulation of the cisterna magna, for a total of 17 samples measured to support PK model development. ECF samples for analysis of dopamine were collected from a separate group of five animals (microdialysis probes inserted into the PFC and caudate nucleus), for a total of 70 samples measured for dopamine in each brain location.
Surgery for implantation of the microdialysis guide cannula and CSF cannula was conducted under isoflurane anesthesia (2%, with 500 mL/min O2), using bupivacaine/epinephrine for local analgesia and finadyne for peri/post-operative analgesia. To support analysis of D-amphetamine in brain ECF, a guide cannula (Brainlink B.V., Groningen, The Netherlands) was inserted into the PFC to achieve the following probe tip coordinates: anteroposterior, + 3.4 mm from bregma; lateral, -0.8 mm (left) from midline; and ventral, -5.0 mm from dura. To support analysis of dopamine in ECF, a guide cannula was inserted into the caudate nucleus to achieve the following probe tip coordinates: anteroposterior, + 0.9 mm from bregma; lateral, -3.0 mm (left) from midline; and ventral, -6.0 mm from dura. In the same animal, a guide cannula (Brainlink) was also inserted into the PFC using the coordinates specified for collection of ECF for analysis of D-amphetamine in this matrix. A CSF-cannula (Brainlink) was inserted 0.45 -0.55 mm deep into the cisterna magna for CSF collection. Coordinates were: anteroposterior, occipital-parietal junction; lateral, 0 mm from midline; ventral, 0.45 -0.55 mm from dura. Finally, a 4.2 cm indwelling cannula
(Brainlink) was inserted into the jugular vein to allow for blood sampling. The cannula was exteriorized through an incision at the top of the head. Animals were allowed at least 2 days to recover from surgery. In all experiments, MetaQuant microdialysis probes (regenerated cellulose membrane, 18 kDa molecular weight cutoff, 216 m outer diameter with 3 or 4 mm open membrane surface for caudate nucleus and PFC, repsectively, Brainlink) were inserted 1 day before an experiment.
On the day of an experiment, microdialysis probes were connected with flexible PEEK tubing to a CMA 102 microdialysis pump (CMA Microdialysis, Solna, Sweden) and perfused as in NHP experiments with artificial CSF at a flow rate of 0.15 L/min, and ultrapurified water as the carrier at a flow rate of 0.8 L/min (CMA 102 pump). Rats were awake and freely moving during the entire course of sample collection.
Dextroamphetamine was administered through the tail vein at t = 0. The formulation was sterile 0.9% sodium chloride and was administered in a volume of 0.5 mL/kg. Time points for ECF collection were the same as those specified for the NHP experiments.
Time points for CSF collection were -60, 0 (pre-dose), and 30, 60, 90, 120, 180, 240 and 300 minutes post-administration of D-amphetamine. Sample volume was 20 L.
There was a maximum of seven samples taken from any given animal and a minimum of 1 hour between samples. Whole blood samples (150 L) were taken at the following times from different animals, with no more than seven samples taken per animal: -60, -15, 0 (pre-dose), and 5, 10, 20, 30, 45, 60, 90, 120, 180, 240 
regression, and the sample concentrations were determined using these calibration curves. Accuracy was verified by quality control samples after each sample series.
Concentrations were calculated with the Analyst data system (Applied Biosystems).
The lower limit of quantitation (LLOQ) for D-amphetamine was 0.1 nM in brain ECF and CSF, 1 nM in plasma, and was 0.02 nM for dopamine in brain ECF.
Pharmacokinetic Analysis
Plasma concentrations (free + plasma protein bound) were converted to unbound concentrations based on an unbound fraction = 0.6 in both species (Baggott et al., 1972) . A one-compartment model best described D-amphetamine pharmacokinetics in plasma for both species (details of model development described in subsequent paragraph). Brain ECF and CSF concentrations were incorporated as peripheral compartments, with one-way ECF to CSF directional clearance connecting the two brain compartments. Transfer characteristics between plasma and the two brain compartments were modeled using either a single intercompartmental clearance (Q) or separate parameters for the uptake and efflux apparent distributional clearances (Clin and Clout). Equations 1 (plasma,p), 2 (ECF), and 3 (CSF) below provide a mathematical description of the final model, where dA/dt refers to the rate of change of the amount (pmoles) of D-amphetamine in a given compartment, with Ap = dose at time zero, and Aecf = Acsf = 0 at time zero. Remaining terms are defined below and in Table 1 .
The unbound volume of distribution of D-amphetamine in the brain (Vb) was estimated using a computational approach (Spreafico and Jacobson, 2013 ). This approach is based on estimation of Kp,uu,cell, which is the unbound intracellular concentration to unbound ECF concentration ratio at distributional equilibrium (Fridén et al., 2011) . For rats, estimation of this parameter was based on a Log P = 1.76 and pKa = 9.9 for Damphetamine ( Fridén et al., 2011) . Rat CSF volume (Vcsf) was 0.25 mL (Cserr and Berman, 1978) . For NHP, Vb and Vcsf were allometrically scaled from the rat value using the following equation: Vb,NHP = Vb,rat x (NHP weight/rat weight). A nominal NHP weight of 5 kg and rat nominal weight of 0.462 kg were used. The final structural model shown in Figure 1 was the same in both species.
Pharmacokinetic modeling of D-amphetamine in both species was conducted using a non-linear mixed-effect (NLME) population analysis approach (Phoenix 8.2, Pharsight Corporation, Certara, L.P., Princeton, NJ, USA). This approach enables model development by consideration of all collected concentrations in the various matrices (plasma, ECF and CSF) at the same time. In effect, all the data are pooled to support development of a model that simultaneously minimizes differences between all observed and model-predicted concentrations. In this way, population modeling requires fewer samples than traditional modeling, which seeks to describe observed data in each animal, requiring rich data in each sampled biofluid, and then uses
descriptive summary statistics (e.g. mean ± standard deviation) to report each model parameter.
There are two components to population models: model structure (as defined in the preceding paragraph) and the statistical model that partitions sources of variability to either between-subject variability in the various PK parameters, or remaining unexplained variability. Model structure evaluation was based on the following goodness-of-fit criteria: minimization of the differences between observed and model- 
Amphetamine Exposure versus Dopamine Response Relationship Analysis
To support this analysis, mean data obtained from several published studies in rats and one study in NHPs were digitized using Enguage digitizer (https://github.com/markummitchell/engauge-digitizer/releases). For NHPs, dopamine response over time in PFC and caudate nucleus followed 0.3, 0.5 or 1.0 mg/kg IV bolus doses of D-amphetamine to male rhesus macaques (Jedema et al., 2014) . For rats, dopamine time courses in PFC were determined following D-amphetamine doses of either 0.5 or 1.0 mg/kg (Moghaddam et al., 1990; Pum et al., 2007; Kleijn et al., 2012) .
Dopamine time courses in the striatum were determined following doses ranging from 0.5 -5 mg/kg (Bardo et al., 1999; Kuczenski et al., 1989; Melega et al., 1995) . Along with mean 0.1 mg/kg data, these data are summarized in Supplemental Figure 1 . In NHPs, dose-independent PK of D-amphetamine over the 0.1 to 1.0 mg/kg dose range was assumed. In the rat, similar half-life in plasma over the dose range (1.2 hours at 0.1 mg/kg and 0.9 hours at 5.0 mg/kg) supports dose-independent PK (Melega et al., 1995) .
Results
Concentrations of D-amphetamine in the three biological matrices following a 0.1 mg/kg intravenous bolus dose are summarized in Figure 2 for both NHPs and rats.
There were no detectable D-amphetamine levels in any of the sampled matrices for the two species prior to drug administration. In both species, ECF concentrations had equilibrated with plasma by the second sampling interval (30 -60 minutes). Decline in brain ECF and CSF concentrations paralleled those in plasma from the first hour onwards. In a given species, concentrations in these two brain fluids were also similar, an indication of rapid within brain equilibration. Since plasma concentrations are presented as unbound levels (corrected for plasma protein binding of D-amphetamine, Baggot et al., 1972) , differences between these and brain concentrations could indicate transporter-mediated passage across either the blood-brain barrier (BBB) or blood-CSF barrier (BCSF). On average, in NHPs brain ECF and CSF concentrations were slightly higher (< 2-fold) than plasma. In rats, in which the three matrix concentrations were measured simultaneously, brain ECF and CSF concentrations were again slightly higher estimates (Fuh et al., 2002; Hutchaleelaha et al., 1994; Melega et al., 1995) , and reflected much faster elimination than observed in NHPs based on application of the same equation (5.5 hours). This estimated plasma half-life in NHPs is similar to a reported estimate of 10 hours (Downs et al., 1977.) difference resulted in a clockwise hysteresis, which is signatory for acute tolerance development (Hammarlund et al., 1985; Louizos et al., 2014) . A similar analysis was conducted in the rat based on dopamine time courses following D-amphetamine doses ranging from 0.1 to 5 mg/kg (shown in Supplemental Figure 1) . Results of these analyses are summarized in Figure 7 . As with NHPs, there was a larger dopamine response in striatum versus PFC following D-amphetamine doses of 0.5 and 1.0 mg/kg.
Also similar to NHPs, clockwise hysteresis was identified at doses between 1 and 5 mg/kg.
Discussion
Existence of highly restrictive anatomical barriers to solute movement into and out of brain parenchyma (BBB) and CSF (BCSFB) often creates marked differences between the time courses of solute concentration in these regions relative to the blood.
Microdialysis has been routinely used to measure neurotransmitters and their associated metabolites, as well as drug concentrations in brain ECF. Its application to characterize CNS physiology and support early efforts regarding the discovery of CNS therapeutics has been widely applied using primarily rats (Kielbasa and Stratford, 2015 ).
An attractive feature of the technique is its ability to provide several concentration measures over time within an animal, thus supporting detailed pharmacokinetic and pharmacodynamic (PKPD) analyses with reduced numbers of animals needed. A useful outcome of these analyses are PKPD models that can be translated from rats to humans using allometric or physiologic-based approaches to predict human CNS exposure and effects. A concern with these analyses, however, relates to the accuracy of these extrapolations, especially when developing drug candidates with novel pharmacologic targets. Judicious application of a non-human primate model that parallels the rodent microdialysis model could be highly advantageous to quell or raise concerns, as results dictate, regarding the suitability of the rodent results to reliably predict PKPD relationships in humans. The objective of the studies conducted was to provide a demonstration that a NHP model, capable of sampling plasma, brain ECF and CSF, and subsequently measuring drug and neurotransmitter response in a relevant Invoking an assumption of similar red blood cell partitioning of D-amphetamine to structurally related methylenedioxymethamphetamine (Ecstasy), which has been estimated to be 1.45 (Garrett et al., 1991) , and correcting for plasma protein binding of 40% for D-amphetamine (Baggot et al., 1972) , estimated uptake clearance (Clin) of the drug in NHPs of 39.6 mL/min translates to 16.5 mL/min brain uptake clearance from blood. This estimate is approximately 25% of brain blood flow in the 5 kg NHPs used, 72 mL/min (Davies and Morris, 1993) , and is consistent with the drug's rapid onset of action in humans as early as 30 minutes following oral fasted administration (Clinical database, 2015) . In rats, after correcting for red blood cell partitioning and plasma protein binding, brain uptake clearance of D-amphetamine was even faster than brain blood flow (2.4 mL/min in a 462 gram (average) rat), which is not surprising given that peak brain ECF concentration occurred within the 0 -30 minute collection period (Figure 2 ). Uptake to efflux clearance ratios of D-amphetamine were between 1 and 2 in both species, and could indicate contribution of an uptake carrier-mediated process at the BBB, similar to what has been observed for several other drugs that are weak bases (Gharavi et al., 2015) .
As previously noted, it is possible to measure solute concentrations (drugs and their metabolites, as well as neurotransmitters and their metabolites) in brain ECF and CSF in the same animals. When coupled with plasma measures of drug concentration, PKPD models can be developed to describe solute concentration time courses, and these used proactively to simulate the effects of dose changes, for example, on CNS drug exposure and effects. Although not obligatory, use of population modeling approaches is powerful as it enables simultaneous analysis of concentrations in several matrices that may be obtained from different animals and/or after separate drug administration occurrences. This population analysis approach would be highly applicable to NHP CNS (brain parenchyma and CSF) exposure studies, since the surgical preparation of the subjects is intended to be sub-chronic in order to enable the subjects to be used on multiple occasions, preferably for a specific drug. Application of a population approach in the present case was appropriate since multiple animals, with varying combinations of brain ECF sampling for drug exposure and dopamine effect, and CSF and plasma sampling for drug exposure, were used. For example, brain ECF
measures of D-amphetamine were from four sites in one animal, and were from another animal for dopamine measures in the same brain regions. In addition, separate occasions and multiple NHPs (a total of 3) were used for analysis of D-amphetamine exposure in plasma and CSF. Thus, D-amphetamine disposition in CNS was characterized using a sparse sampling approach in a small number of animals. In this present case, only one animal was used to determine drug exposure in brain ECF, albeit with four probes in that animal. The specific purpose was to demonstrate the technical feasibility to sample multiple brain sites simultaneously, if so desired, such as to investigate regional differences in brain PKPD. In our development of the PK model that connects plasma to brain ECF and CSF exposure, we decided to use all four sites.
The assumption in doing so was that variability in amphetamine exposure in the four brain regions (Figure 2 , inset) was due to method variability (e.g. probe performance); however, to determine if this was not the case, multiple animals would need to be evaluated. In addition, it would be advisable to use multiple animals to support evaluation of inter-animal variability, which was a limitation of the current analysis.
Identification of rapid uptake of D-amphetamine into the brain ECF and decline of these concentrations in parallel with plasma in both rats and NHPs, indicates excellent CNS disposition properties (BBB permeability and distribution) of the drug that are preserved across species. This good cross-species translation of CNS disposition would increase confidence regarding an expectation of similar performance in humans.
However, D-amphetamine represents an ideal scenario given its excellent physicochemical properties (MW, Log P, and hydrogen bonding capacity) that portend fast and extensive BBB permeation. In cases of novel CNS drug targets and/or (Jedema et al., 2014; Moghaddam et al., 1993) . Such differences have also been reported in rats (Mazei et al., 2002; Moghaddam et al., 1990; Pehek, 1999) . In both species higher density of dopamine terminals in the striatum compared to the PFC is the attributed cause (Haber et al, 1995; Sesack et al., 1998) . This consistent regional difference, preserved in rodent and primate brain, resulted in greater capacity of the striatum than the PFC to respond to a D-amphetamine challenge, as reflected by a larger striatal response in both species as dose increased (Figures 6 and 7 ). This similarity across species was not limited to this instance. A second example pertained to decline of dopamine levels occurring faster than drug loss. In this case, the two brain regions were similar. Graphical analysis of this more rapid decline in response relative to drug loss portrayed as clockwise hysteresis, an observation that suggests development of an acute tolerance response (Louizos et al., 2014) in both species.
Key to demonstrating this pattern was simulation of D-amphetamine concentrations in brain ECF over a range of doses, which was made possible by the population PK models developed for both species. Acute tolerance to stimulants in NHPs has also
been reported by others (Bradberry, 2000; Downs and Braude, 1977; Laurelle, 2000) , and was suggested by Jedema et al. (2014) specifically for D-amphetamine. It would be interesting to couple other PD measures of D-amphetamine response, such as fast scan cyclic voltammetry, which has high temporal and spatial resolution, for measuring dopamine levels and neuron-glial metabolic coupling based on oxygen and pH changes, as recently reported in NHPs (Ariansen et al., 2012) . Acute tolerance to Damphetamine has been reported in humans (Angrist et al., 1987; Brauer et al., 1996; Dolder et al., 2017) . In these clinical studies, evidence of acute tolerance was based on subjective measures of drug-induced feelings of euphoria relative to plasma drug concentrations. Clockwise hysteresis was reported, which contrasted with absence of hysteresis between cardiovascular effects of the drug (systolic blood pressure and heart rate) in relation to concentration.
Measurement of both D-amphetamine exposure and dopamine response in brain ECF, as presently reported, provides additional information (relative to measurement of dopamine alone), potentially providing deeper mechanistic insight into drug action (Mager et al., 2003) . Ability to measure and model drug exposure in association with temporal alterations in levels of endogenous substances at the site of drug action in the brain over a range of doses would support development of mechanistic PKPD models.
In the case of D-amphetamine, measurement of dopamine and/or its metabolites, or other biogenic amine time courses could expand our understanding of the mechanism of acute tolerance development and how relationships might change with chronic dosing, potentially supporting new approaches to treat cognition and/or drug abuse.
One promising approach pertains to inhibition of protein kinase C (PKC) by a BBB permeable tamoxifen analog (Carpenter et al., 2017 envisioned, and these justify application of this primate-based in vivo approach, even while significant strides are being made to monitor chemicals in human brain using microdialysis (Varner et al., 2017; Booth et al., 2018) . These include 1) enhanced confidence in applicability of rodent CNS exposure and efficacy models for novel drug targets that are hypothesized to alter endogenous substances in humans; 2) primatelevel target validation of novel drug targets; 3) mechanistic inquiries into PKPD relationships; 4) allometric scaling of NHP brain kinetics to predict human brain exposure; and 5) brain ECF-to-CSF exposure relationships in NHPs to predict human brain extracellular fluid exposure based on CSF exposures in humans.
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